BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2014 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

When details from Zontivity’s TRA 2P trial in patients were released, many experts felt that the sponsor would have difficulty getting physicians to use the drug or that it would have limited use in specialist centers, due to the bleeding risk. However, when Zontivity was approved (May 8, 2014) for use with clopidogrel/aspirin, its label was relatively benign, not reporting bleeding in the overall trial, which included stroke/TIA patients who had excessive bleeding with the drug, or in ACS trial, where there was also excessive bleeding.

As a result, BMT performed this survey of 10 US cardiologists (5 interventionalists and 5 non- interventionalists) for an updated view of possible usage. We were also interested in projected usage because current P2Y12 antagonists (clopidogrel, Effient, and Brilinta) are generally recommended for a year after an ACS event. While not yet in the guidelines, Zontivity has a more general indication for any prior MI.

To purchase the Zontivity Approval Project Usage Pulse Survey, click the link at the top of the page.

For our disclosures, please read the BioMedTracker Research Standards.